Evidence map›Paper›PMID 40307541›Full record

ArticleArchives of virology2025

Seroprevalence of anti-influenza antibodies in humans and characterization of seasonal influenza viruses isolated in Russia during the 2023-2024 flu season.

Svetlana V Svyatchenko, Nikita D Boldyrev, Anastasia S Panova, Natalia P Kolosova, Kiunnei N Shadrinova, Natalia I Goncharova, Galina S Onkhonova, Alina R Muratova, Alexey V Danilenko, Elena I Danilenko and 7 more

Abstract read
PubMed Publisher
In one paragraph

Article in Archives of virology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Svetlana V SvyatchenkoState Research Center of Virology and Biotechnology "Vector", Rospotrebnadzor, Koltsovo, Novosibirsk, 630559, Russia. svyatchenko_sv@vector.nsc.ru.ORCID http://orcid.org/0000-0003-4573-5783
Nikita D BoldyrevState Research Center of Virology and Biotechnology "Vector", Rospotrebnadzor, Koltsovo, Novosibirsk, 630559, Russia.ORCID http://orcid.org/0000-0001-8854-0287
Anastasia S PanovaState Research Center of Virology and Biotechnology "Vector", Rospotrebnadzor, Koltsovo, Novosibirsk, 630559, Russia.ORCID http://orcid.org/0000-0003-0556-0552
Natalia P KolosovaState Research Center of Virology and Biotechnology "Vector", Rospotrebnadzor, Koltsovo, Novosibirsk, 630559, Russia.ORCID http://orcid.org/0000-0001-8865-8592
Kiunnei N ShadrinovaState Research Center of Virology and Biotechnology "Vector", Rospotrebnadzor, Koltsovo, Novosibirsk, 630559, Russia.ORCID http://orcid.org/0009-0002-4351-8267
Natalia I GoncharovaState Research Center of Virology and Biotechnology "Vector", Rospotrebnadzor, Koltsovo, Novosibirsk, 630559, Russia.ORCID http://orcid.org/0009-0001-6753-597X
Galina S OnkhonovaState Research Center of Virology and Biotechnology "Vector", Rospotrebnadzor, Koltsovo, Novosibirsk, 630559, Russia.ORCID http://orcid.org/0000-0002-1547-1708
Alina R MuratovaState Research Center of Virology and Biotechnology "Vector", Rospotrebnadzor, Koltsovo, Novosibirsk, 630559, Russia.ORCID http://orcid.org/0009-0003-5379-6452
Alexey V DanilenkoState Research Center of Virology and Biotechnology "Vector", Rospotrebnadzor, Koltsovo, Novosibirsk, 630559, Russia.ORCID http://orcid.org/0000-0003-3214-2794
Elena I DanilenkoState Research Center of Virology and Biotechnology "Vector", Rospotrebnadzor, Koltsovo, Novosibirsk, 630559, Russia.
Andrey S GudymoState Research Center of Virology and Biotechnology "Vector", Rospotrebnadzor, Koltsovo, Novosibirsk, 630559, Russia.ORCID http://orcid.org/0000-0001-6952-6412
Natalia N VasiltsovaState Research Center of Virology and Biotechnology "Vector", Rospotrebnadzor, Koltsovo, Novosibirsk, 630559, Russia.ORCID http://orcid.org/0009-0001-1548-5608
Marina L EgorovaState Research Center of Virology and Biotechnology "Vector", Rospotrebnadzor, Koltsovo, Novosibirsk, 630559, Russia.
Ksenia I IvanovaState Research Center of Virology and Biotechnology "Vector", Rospotrebnadzor, Koltsovo, Novosibirsk, 630559, Russia.ORCID http://orcid.org/0009-0002-3191-1360
Tatiana N IlyichevaState Research Center of Virology and Biotechnology "Vector", Rospotrebnadzor, Koltsovo, Novosibirsk, 630559, Russia.ORCID http://orcid.org/0000-0002-2354-7688
Vasily Y MarchenkoState Research Center of Virology and Biotechnology "Vector", Rospotrebnadzor, Koltsovo, Novosibirsk, 630559, Russia.ORCID http://orcid.org/0000-0002-1339-6732
Alexander B RyzhikovState Research Center of Virology and Biotechnology "Vector", Rospotrebnadzor, Koltsovo, Novosibirsk, 630559, Russia.ORCID http://orcid.org/0000-0002-7009-0748

Funding

Federal Budgetary Research Institution State Research Center of Virology and Biotechnology (FBRI SRC VB) VECTOR, Rospotrebnadzor, Russia State assignment
6 · The paper itself

Abstract

The 2023-2024 flu season in Russia was dominated by influenza A(H3N2) viruses. In this study, we isolated seasonal influenza viruses from human respiratory specimens, analyzed their genetic and antigenic properties, and assessed their susceptibility to neuraminidase inhibitors. In total, we isolated 207 influenza virus isolates. Of them, 95.2% were subtyped as A(H3N2), 1.9% as A(H1N1)pdm09, and 2.9% as B/Victoria influenza viruses. The hemagglutinin sequences of the A(H3N2) isolates showed that they belonged to several subclades within the 2a.3a.1 genetic group, with the J2 subclade being predominant. Despite their genetic diversity, all A(H3N2) strains tested using a hemagglutination inhibition assay were antigenically similar to the egg-propagated vaccine strain A/Darwin/09/2021(H3N2). The B/Victoria virus isolates belonged to the C.5 and C.5.7 subclades of the genetic group V1A.3a.2 and were antigenically similar to cell- and egg-propagated variants of the vaccine strain B/Austria/1359417/2021. All of the A(H1N1)pdm09 isolates belonged to the 6B.1A.5a.2a genetic clade and were well-recognized by a ferret antiserum raised against a cell-propagated A/Wisconsin/67/2022(H1N1pdm09)-like reference strain. All of the tested isolates were susceptible to oseltamivir and zanamivir, including two A(H1N1)pdm09 strains with an NA-S247N substitution. Seroprevalence analysis showed that 60%, 54%, and 46% of the human blood samples tested were seropositive for the A(H3N2), A(H1N1)pdm09 and B/Victoria antigens from the 2022-2023 vaccine.

Indexed as

Antibodies, ViralInfluenza A Virus, H1N1 SubtypeInfluenza A Virus, H3N2 SubtypeInfluenza, HumanAdolescentAdultAgedAnimalsAntiviral AgentsChildChild, PreschoolFemaleHemagglutination Inhibition TestsHemagglutinin Glycoproteins, Influenza VirusHumansInfluenza B virusAntibodies, ViralAntiviral AgentsHemagglutinin Glycoproteins, Influenza Virus

Identifiers

PMID40307541

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.